Kinsale Capital Group Inc. Has $9.65 Million Stock Position in Amgen Inc. $AMGN

The excerpt argues that institutional investors increasingly influence pharma CEOs, shifting priorities toward shareholder returns. A 2021 US House Oversight report on 14 major drug companies found 2016–2020 spending of $577B on buybacks/dividends versus $56B more than R&D, with executive pay over $3.2B. It also cites AbbVie’s Humira-related “anticompetitive R&D” and merger-driven declines in innovation.

Reuters reports that heads of Global Capability Centres in India are deploying AI across marketing, finance and HR to automate repetitive tasks. Examples include Apollo Hospitals’ Microsoft-backed clinical assistant, Catalyst Brands’ AI-generated product visuals, and Kimberly-Clark’s influencer tools. Novo Nordisk uses AI for regulatory and safety analysis, while IBM and Workday expand AI in monitoring and HR/finance.

Amgen's CFO Peter Griffith is retiring, with Thomas Dittrich rejoining as the new CFO on September 1, 2026. Simultaneously, shareholders rejected a proposal for an independent board chair, highlighting a focus on leadership continuity versus oversight. These changes are analyzed for their potential influence on Amgen's investment narrative, especially concerning its diversified drug portfolio, R&D spend, and competitive pressures.

Legato Capital Management LLC has purchased a new position of 8,328 shares in Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, valued at approximately $2.73 million. This comes as other institutional investors have also adjusted their holdings in the company. Amgen recently announced a quarterly dividend of $2.52 per share, payable on June 5th, with a current annualized yield of 3.0%.

Amgen Inc. (NASDAQ: AMGN) stock was trading near $330 after a report revealed that at least 20 people in Japan died and 22 others developed liver injuries after taking Amgen's rare disease drug. Japanese seller Kissei Pharmaceutical advised doctors to stop prescribing the drug. This news raises concerns about regulatory and reputational implications for Amgen, even as the company's Q1 2026 results showed strong growth for other products and an anticipated CFO transition occurred.

This Rx Rundown provides a comprehensive overview of recent activities in the medical marketing and pharmaceutical industries, including significant mergers, acquisitions, and collaborations. It details FDA approvals and clinical holds, major funding rounds, and notable layoff announcements. The article also covers key industry news such as drug trial results, legal settlements, and public health initiatives.